<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Novel strategies that target the epidermal growth factor receptor (EGFR) have led to the clinical development of monoclonal antibodies, which treat <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) but only subgroups of patients with increased <z:mp ids='MP_0002169'>wild type</z:mp> KRAS and EGFR gene copy, respond to these agents </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, resistance to EGFR blockade inevitably occurred, making future therapy difficult </plain></SENT>
<SENT sid="2" pm="."><plain>Novel bio-imaging (BOI) methods may assist in quantization of EGFR in mCRC tissue thus complementing the immunohistochemistry methodology, in guiding the future treatment of these patients </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was to explore the usefulness of near infrared-labeled EGF (EGF-NIR) for bio-imaging of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> using in vitro and in vivo orthotopic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> models and ex vivo human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>We describe the preparation and characterization of EGF-NIR and investigate binding, using BOI of a panel of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell culture models resembling <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues </plain></SENT>
<SENT sid="5" pm="."><plain>EGF-NIR was specifically and selectively bound by EGFR expressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, the intensity of EGF-NIR signal to background ratio (SBR) reflected EGFR levels, dose-response and time course imaging experiments provided optimal conditions for quantization of EGFR levels by BOI </plain></SENT>
<SENT sid="6" pm="."><plain>EGF-NIR imaging of mice with HT-29 orthotopic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> indicated that EGF-NIR is more slowly cleared from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and the highest SBR between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> adjacent tissue was achieved two days post-injection </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, images of dissected tissues demonstrated accumulation of EGF-NIR in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and liver </plain></SENT>
<SENT sid="8" pm="."><plain>EGF-NIR specifically and strongly labeled EGFR positive human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues while adjacent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissue and EGFR negative tissues expressed weak NIR signals </plain></SENT>
<SENT sid="9" pm="."><plain>This study emphasizes the use of EGF-NIR for preclinical studies </plain></SENT>
<SENT sid="10" pm="."><plain>Combined with other methods, EGF-NIR could provide an additional bio-imaging specific tool in the standardization of measurements of EGFR expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues </plain></SENT>
</text></document>